Best Pharmaceuticals for Children Act (BPCA)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH) in collaboration with the U.S. Food and Drug Administration (FDA) and National Heart Lung and Blood Institute (NHLBI), NIH

Primary Pediatric Hypertension Workshop: Epidemiology and Treatment Gaps September 25, 2017

RECORDING LINK SUMMARY

Please find four recording links below. Under each link is listed the contents of that recording along with timestamps of each session (Hour:Minute:Second).

If prompted to enter a password, click Cancel. No password is needed to access the recordings.

https://infinityconferences.adobeconnect.com/plx1iqx061eq/

Welcome and Introductions (0:04:30-0:13:09)
 Anne Zajicek, Pharm.D., Gilbert Burckart, Pharm.D., Perdita Taylor-Zapata, M.D.

MODULE 1: Primary Pediatric Hypertension – Epidemiology and Current Diagnosis Criteria

• What Do We Know? Overview of Hypertension in Pediatrics, Epidemiology and Diagnosis (0:14:28-0:48:45)

Carissa Baker-Smith, M.D. Brian Kit, M.D., M.P.H.

 Research Activities to Address Knowledge Gaps Related to Blood Pressure Screening and Control in Children (0:48:55-1:10:02)

Carrie Klabunde, Ph.D., Iris Mabry-Hernandez, M.D.

• Clinical Decision Trees: Particularly in Primary Care, Can it be Done and How? (1:10:36-1:38:02)

David Kaelber, M.D., Ph.D., M.P.H.

• DISCUSSIONS (1:38:15-2:06:35)

https://infinityconferences.adobeconnect.com/pvynieo7bbnn/

MODULE 2: Hypertension Pathophysiology – What Do We Know? Where Are the Gaps?

- Mechanisms of Elevated Blood Pressure and the Rationale for Treatment (0:02:00-0:21:50)
 Julie R. Ingelfinger, M.D.
- Role of Obesity (0:21:55-0:46:44)
 Aaron Kelly, Ph.D.
- Markers of Atherosclerosis (0:46:50-1:11:45) Elaine Urbina, M.D., M.S.
- CV Outcomes: Short-term and Long-term Impact of Hypertension (1:11:50-1:39:00) Stephen Daniels, M.D., Ph.D.
- Discussions (1:39:25-1:49:59)

https://infinityconferences.adobeconnect.com/pr6u1icyjdot/

MODULE 3: Hypertension Treatment – Current Knowledge and Future Directions

- Hypertension Diagnosis and Management in High-Risk Populations (0:05:45-0:39:00) Joseph Flynn, M.D.
- Trials of Hypertension in Pediatric Populations (0:39:12-1:01:35)
 Jennifer Li, M.D.
- Considerations in Assessing Short- and Long-term Safety of Medications for Pediatric Hypertension (1:01:44-1:17:52)
 Ann McMahon, M.D.
- Hypertension Treatment (Pharmacologic): Novel Approaches and New Horizons (1:18:05-1:46:23)
 Ronald Portman, M.D.

https://infinityconferences.adobeconnect.com/py7y5p4wj1b7/

- DASH Approach to Treatment in Hypertensive Youth (0:00:00-0:31:02) Sara Couch, Ph.D.
- Lifestyle Modifications in Hypertension Treatment (0:31:10-0:41:25)
 Janet de Jesus
- DISCUSSIONS (0:41:30-1:09:45)
- Hypertension Research: Next Steps (0:41:30-1:09:45)